
Auro Laboratories Ltd is Rated Strong Sell
2026-11-19 10:10:57Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd is Rated Strong Sell
2026-10-29 10:12:21Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 October 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd is Rated Strong Sell
2026-10-18 10:10:30Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 July 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 18 October 2026, providing investors with the latest perspective on the company’s position.
Read More
Auro Laboratories Ltd is Rated Strong Sell
2026-10-07 10:10:52Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd Valuation Shift Signals Price Attractiveness Change
2026-10-06 08:00:16Auro Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting changing investor sentiment and sector dynamics. Despite a recent downgrade to a Strong Sell rating, the company’s valuation metrics and comparative performance within the Pharmaceuticals & Biotechnology sector warrant a detailed examination for investors seeking clarity on price attractiveness and future prospects.
Read More
Auro Laboratories Ltd Valuation Shifts Signal Price Attractiveness Change
2026-09-29 08:00:11Auro Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, with its price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving from very expensive to expensive territory. This change, coupled with a recent downgrade in its Mojo Grade to Strong Sell, signals a deteriorating price attractiveness relative to both its historical averages and peer group benchmarks.
Read More
Auro Laboratories Ltd is Rated Strong Sell
2026-09-26 10:10:31Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 September 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd is Rated Strong Sell
2026-09-15 10:11:10Auro Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Auro Laboratories Ltd Valuation Shifts Signal Heightened Price Risk Amid Sector Comparisons
2026-09-03 08:00:24Auro Laboratories Ltd has seen a marked shift in its valuation parameters, moving from an already expensive rating to a very expensive one, raising concerns about its price attractiveness relative to historical levels and peer benchmarks. Despite a recent 6.32% intraday gain, the micro-cap pharmaceutical company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest investors should exercise caution amid sector volatility and mixed financial metrics.
Read MoreDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
19-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Siddhartha Deorah HUF
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSEAuro Laboratories Limited has submitted clippings of newpaper publications of the unaudited financial Results for the quarter and half year ended September 30 2026.
Board Meeting Outcome for Dated November 13 2026.
13-Nov-2026 | Source : BSEAuro Laboratories Limited has submitted the outcome of the Board Meeting dated November 13 2026.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available